D
uring the last decade, a large array of viral and nonviral vector systems was developed for gene therapy applications. Numerous clinical trials are currently underway, and many more are intended to be undertaken within the near future. Consequently, there is an urgent need for improved therapy control and evaluation protocols. However, monitoring of important gene therapeutic features (e.g., expression levels, expression kinetics, and the spatial distribution of transduced therapeutic genes) is still unsatisfactory. 1 Conventional procedures for in vivo monitoring of therapeutic gene transfer are based on repetitively collected serum and/or tissue probes used for molecular characterization of the therapeutic DNA, RNA, and/or protein. These highly sensitive and specific techniques are laborious and cannot be applied ad libitum, especially when tissue probing is required for transgene detection. Adequate, alternative, noninvasive, diagnostic tools have not been provided thus far.
Here, the use of positron emission tomography (PET) as the most sophisticated nuclear imaging technology currently available is suggested. PET is a true imaging technique that tracks positrons, which result in the emission of two 511-keV photons on annihilation with an electron. With PET, a positron-emitting radioisotope is used to label ubiquitous substrates such as 18 F-2-fluoro-2-deoxy-D-glucose glucose, which is taken up by metabolically active cells or 124 I-labeled monoclonal antibody (mAb), for radiation treatment planning. 2 PET provides quantitative images that can noninvasively trace the hypermetabolic regions within the living body, reflecting distinct clinical situations.
Most of the gene therapy monitoring studies carried out thus far have been restricted to the scintigraphic or tomographic imaging of the enzymatic activity of suicide genes. [3] [4] [5] [6] [7] [8] [9] [10] However, in the future, monitoring techniques will be required which are not restricted to a subset of therapeutic genes (e.g., suicide genes), but are generally applicable. [11] [12] [13] For this purpose, versatile transduction tag systems have to be developed. The goal is to coexpress traceable genetic tags that mark therapeutic gene expression irrespective of the nature of the therapeutic gene employed.
Recently, several laboratories have employed the lowaffinity nerve growth factor (NGF) receptor (LNGFR) or a C-terminal-deleted LNGFR version (⌬LNGFR) as a cell surface marker for the detection and purification of primitive and committed hematopoietic progenitor cells. 14 -19 The presence of ⌬LNGFR ϩ CD34 ϩ cells after long-term culture suggested that ⌬LNGFR is stably integrated and stably expressed in retroviral vectortransduced CD34 ϩ cells grown ex vivo. 16, 18 Recent data indicated that ex vivo-transduced human lymphocytes expressing ⌬LNGFR can be safely transplanted into neoplastic patients. 20 Moreover, these transduced lymphocytes were not found to elicit an immune response to ⌬LNGFR when transplanted into the recipient host. 16 Taken together, all of these properties identify ⌬LNGFR as an ideal transduction tag receptor molecule.
The aim of the present study was to develop an experimental platform for the rational design and in vitro testing of suitable receptor-ligand couples as components of future transduction tag systems for noninvasive gene therapy monitoring applications. Here, the feasibility of the ⌬LNGFR/NGF transduction tag system was investigated. This system employs a C-terminal-deleted version of LNGFR (p75mut or ⌬LNGFR) and its natural ligand NGF as well as a p75-specific mAb (anti-p75 mAb).
MATERIALS AND METHODS

Cell culture, transfections, and generation of recombinant retroviral particles
The cell lines NIH 3T3 (3T3) (Swiss mouse embryo) and PC12 (rat adrenal pheochromocytoma) were obtained from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Rat Morris hepatoma 3924A (MH) specimens were obtained from the German Cancer Research Center (Heidelberg, Germany). The retroviral packaging cell lines PE501 and PA317 21 were obtained from A. D. Miller (Fred Hutchinson Cancer Research Center, Seattle, Wash). The cell lines 3T3, MH, PE501 and PA317 were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf sera (FCS). PC12 cells were grown on collagen-coated dishes (Biocoat/Falcon, Heidelberg, Germany) and maintained in RPMI 1680 supplemented with 10% FCS and 5% horse sera. All cells were cultivated in a humidified incubator at 37°C in a 5% CO 2 atmosphere. Media and supplements were purchased from Life Technologies (Eggenstein, Germany).
The retroviral vector pL⌬NSN 16 was kindly provided by Dr. R. Rüger (Boehringer Mannheim, Penzberg, Germany). Recombinant pL⌬NSN-transducing retroviral particles were generated by standard techniques. Briefly, PE501 ecotropic packaging cells (5 ϫ 10 5 per 6-cm Petri dish) were transfected with 3 g of pL⌬NSN plasmid DNA in the presence of Lipofectamine (Life Technologies, Gaithersburg, Md) according to the manufacturer's instructions. After 48 hours, supernatants were collected and used for incubation on PA317 packaging 
cells (5 ϫ 10
5 cells per 6-cm Petri dish) for 3 hours in the presence of 4 g/mL Polybrene (Sigma, Deisenhofen, Germany). After another 48 hours, the cells were replated with 600 g/mL G418 added to the medium. Single cell colonies were isolated 7-9 days after plating using small pieces of sterile filter paper soaked in trypsin/ethylenediaminetetraacetic acid (Life Technologies). One producer clone was selected with a titer of 6 ϫ 10 5 colony-forming units/mL. Transductions of 3T3 and MH cells followed the same protocol. Isolated clones were screened for p75mut expression by immunocytochemical detection and fluorescence microscopy using a p75-specific mAb (IgG anti-p75 mAb detecting an extracellularly located p75 epitope; Boehringer Mannheim) followed by secondary staining with fluorescein isothiocyanate-conjugated sheep antimouse IgG antibody (Boehringer Mannheim, Germany). For further studies, distinct 3T3-p75mut and MH-p75mut clones were selected according to relative staining intensities.
Ligand iodination
Human recombinant NGF (R&D Systems, Wiesbaden, Germany) was radioiodinated with 125 I (Amersham-Buchler, Braunschweig, Germany) and 124 I 22, 23 using N-bromosuccinimide (NBS) (Sigma) as an oxidizing agent. 24 NGF was dissolved in cold PPB (0.13 M sodium-phosphate buffer, pH 7.4) followed by the addition of radioiodine ( 125 I: 0.5 mCi per 10 g of protein;
124 I: 33 Ci per 10 g protein) and NBS in a stoichiometric ratio of 6 mol NBS to 1 mol dimerized NGF. The reaction mixture was incubated on ice for 5 minutes. Anti-p75 mAb was radiolabeled with 125 I by lactoperoxidase. 25 Labeling efficiency was assessed through thin layer chromatography on silica plates, and plates were read under a digital autoradiograph (EG&G Berthold, Wildbad, Germany). The specific activities of 125 I-NGF, 125 I-anti-p75 mAb, and 124 I-NGF were determined to be 1.9 MBq/g, 5.8 MBq/g, and 0.1 MBq/g, respectively. Due to an average incorporation efficiency of 95-98% for the NBS reaction, purification was not required. However, the lactoperoxidase reaction occasionally yielded incorporation efficiencies below 90%, requiring purification which was done using Micro Bio-Spin Chromatography P6 columns (BioRad Laboratories, München, Germany). The biological activity of iodinated NGF was determined using the PC12 neurite outgrowth assay. 26 
Binding of labeled ligands to target cells
Binding of iodinated NGF to cells in suspension was performed as described previously. 27 Briefly, cells were harvested by incubation with 10 mM of ethylenediaminetetraacetic acid in phosphate-buffered saline (PBS) for 5 minutes and thoroughly suspended. Samples of 10 6 cells were incubated with labeled NGF (10 ng/mL) for a determination of specific binding and additionally with unlabeled NGF (2 g/mL) for a determination of nonspecific binding in a total volume of 1 mL of PPB for 30 minutes at room temperature; next, samples were washed and lysed in 2% sodium dodecyl sulfate for ␥-counting. Experiments with cells in suspension were done in triplicate.
Binding assays on intact cells were carried out by growing target cells in multichamber microscopic slides to 80% confluence. Cells were washed once with PBS, and nonspecific binding sites were blocked with 10% FCS, followed by addition of ligands (labeled and unlabeled to determine both specific and nonspecific binding) and incubation at room temperature. Concentrations of NGF were the same as for the suspension experiments, whereas anti-p75 mAb was used at concentrations of 50 ng/mL (labeled) and 10 g/mL (unlabeled), respectively. Cells were washed once with PBS after incubation and completely dried before counting under the MicroImager (Biospace Mesures, Paris, France). Counting times varied between 2 hours and 30 hours depending upon the specific activity of the ligands applied.
RESULTS
LNGFR transduction tag stably expressing cell lines As a prototype gene transfer monitoring transduction tag system, a C-terminal-deleted LNGFR lacking the coding sequence for the intracellular receptor domain (p75mut or ⌬LNGFR 16 ) and its natural ligand NGF were used. A commercially available p75-specific mAb (anti-p75 mAb) was also tested.
In a first step, murine 3T3 fibroblasts as well as rat 3924A MH cells were transduced with the bicistronic retroviral vector pL⌬NSN (Fig 1) , containing the ⌬LNGFR gene under long terminal repeat control and the neo r gene under control of the simian virus 40 enhancer/early promoter, and subsequently cultivated under G418 selection. The expression and correct membrane localization of p75mut were confirmed by indirect immunocytochemistry employing mAb anti-p75 (data not shown). Two pairs of ⌬LNGFR receptor-positive (3T3-p75mut, MH-p75mut) and receptor-negative (controls: 3T3, MH) cell lines were made available for subsequent binding studies with the respective radiolabeled ligands.
Binding of
125 I-radiolabeled NGF to p75mut target cells For the establishment and subsequent optimization of ligand radiolabeling procedures, human recombinant NGF was first radiolabeled with the non-positron-emitting nuclide 125 I employing NBS as oxidizing agent. The radiochemical yields ranged from 95% to 98%. The biological activity of 125 I-NGF was determined to be 80% of the biological activity of unlabeled NGF.
Samples of 10 6 target cells (3T3-p75mut, MH-p75mut, 3T3 and MH (negative controls), and PC12 (positive control)) were incubated for 30 minutes at room temperature either with 125 I-radiolabeled NGF (10 ng/mL) alone or additionally with a 200-fold excess of unlabeled NGF (2 g/mL) for quantification of nonspecific ligand binding. After cell lysis, samples were analyzed in a conventional ␥-counter. Specific binding of 125 I-radiolabeled NGF was found for the receptor-positive cell lines 3T3-p75mut, MH-p75mut, and PC12, but not for the receptor-negative control cell lines 3T3 and MH (Fig 2) .
For a direct confirmation of 125 I-NGF binding to the p75mut expressed on intact target cells, samples were grown out in multichamber microscopic slides and incubated again for 30 minutes under ambient conditions either with 125 I-radiolabeled NGF (10 ng/mL) alone or additionally with a 200-fold excess of unlabeled NGF (2 g/mL). Next, samples were washed once with PBS and dried completely. Binding analysis was performed in a MicroImager (Biospace Mesures), which allows a highly sensitive detection and quantification of radiation emitted by the samples. Due to the detection mode that registers the intensified signals on a charge coupled device-matrix, a spatial resolution of up to 15 m can be obtained with the MicroImager.
Employing this method, the intact receptor-positive cell lines 3T3-p75mut, MH-p75mut, and PC12 demonstrated a specific binding of 125 I-radiolabeled NGF (Fig  3) , whereas the receptor-negative control cell lines 3T3 and MH gave rise only to background signals (Fig 3) . Furthermore, the multichamber slide format allows binding analyses to be performed in parallel in four different chambers simultaneously. Specific binding of 125 I-NGF can therefore be assayed in direct comparison with p75mut-transduced and parental wild-type cells (Fig 4) . Signals of high intensity, which are visualized with bright colors (red/yellow, depending upon signal intensity), were demonstrated for receptor-positive 3T3-p75mut, MH-p75mut, and PC12 cells (Fig 4, upper left corners in A and B, left side in C); signals of only low intensity, which are visualized with dark colors (black/ blue, depending upon signal intensity), were found for receptor-negative control 3T3 and MH cells (Fig 4, upper right corners in A and B, right side in C). Background signal intensities were found to be quite low for both receptor-positive as well as receptor-negative cells (Fig 4, lower left and right corners in A-C).
125 I-radiolabeled anti-p75 mAb to p75mut target cells As an alternative approach, the binding specificity of 125 I-radiolabeled anti-p75 mAb to p75mut target cells was also tested. Again, target cell samples were grown out in multichamber microscopic slides (1-2 ϫ 10 5 cells) and incubated for 30 minutes under ambient conditions, now either with 125 I-radiolabeled anti-p75 mAb (50 ng/mL) alone or additionally with a 200-fold excess of unlabeled anti-p75 mAb (10 g/mL). MicroImage analysis demonstrated a specific binding for the intact receptor-positive cell lines 3T3-p75mut and MH-p75mut (Fig  3) , whereas the receptor-negative control cell lines 3T3 and MH gave rise only to background signals (Fig 3) . Direct visualization of individual radiation emission events resulted in microimages with signals of high intensity, which are visualized with bright colors, specifically for receptor-positive 3T3-p75mut and MH-p75mut cells (Fig 4, upper left corners in D and E) ; signals of only low intensity, which are visualized with dark colors, were found for receptor-negative control 3T3 and MH cells (Fig 4, upper right corners in D and E) . Background signal intensities were found to be quite low for both receptor-positive as well as receptor-negative cells (Fig 4, lower left 
and right corners in D and E).
Radiolabeling of NGF with the positron emitting isotope 124 I and first binding studies employing p75 target cells To exemplify future PET applications of the NGF/ ⌬LNGFR prototype transduction tag system, human recombinant NGF was radiolabeled with 124 I (kindly provided by UVK, Essen, Germany) in accordance with the already established labeling procedure for 125 I (see above). Because the radiochemical yield was found to be low (79%), an additional purification step employing gel filtration was added. Consequently, the incorporation rate could be raised up to 98%. However, the specific activity of 124 I-NGF was found to be nearly 20-fold lower than that of 125 I-NGF (0.1 MBq/g versus 1.9 MBq/g, respectively), which is due to the ambiguous cyclotron target and production procedure, significantly lowering the specific activity for ligand labeling.
For subsequent binding studies, 5 ϫ 10 5 target cells (LNGFR ϩ PC12 cells) were incubated for 30 minutes at room temperature either with 124 I-radiolabeled NGF (50 ng/mL) alone or additionally with a 200-fold excess of unlabeled NGF (25 g/mL). Subsequently, PC12 samples were transferred to poly-L-lysine coated multichamber microscopic slides and spun down to attach the cells on chamber bottoms. MicroImager analysis demonstrated signals of high intensity (visualized with bright colors) specifically for receptor-positive PC12 cells (Fig 4, left side in F) . PC12 background signals were found to be of only low intensity (Fig 4, right side in F) .
Thus, this paper reports the first in vitro proof of the PET monitoring/transduction tag approach based on the specificity of 124 I-NGF/LNGFR interactions. 
DISCUSSION
In the newly established field of gene therapy, noninvasive monitoring of clinical trials using imaging techniques is required for improved therapy control and evaluation protocols. 28 It seems to be highly desirable to monitor each and every patient for the following parameters: (a) the transduction efficiency achieved, (b) the tissue/organ distribution of transduced therapeutic genes, (c) the level of therapeutic gene expression, and (d) the duration of therapeutic gene expression. However, especially when solid organs are the target of transduction (e.g., brain, heart, liver), it is not possible to repetitively collect tissue probes from the target organ as well as from a variety of non-target organs/tissues (required for a detailed molecular characterization of the therapeutic DNA, RNA, and/or protein).
Most gene therapy monitoring studies carried out thus far have been restricted to scintigraphic or tomographic imaging of the intracellular enzymatic activity of suicide genes (e.g., herpes simplex virus thymidine kinase, 5- 10,28,29 cytosine deaminase 3 ). As an alternative, coexpression of a transduction tag (i.e., a cell surface-expressed ligand-binding receptor that can be detected using imaging tracers) opens up the possibility for a universal monitoring of gene therapy trials. 13,30 -33 This approach potentially could be applied irrespective of the therapeutic gene employed.
For in vivo monitoring of the tissue/organ tropism of particular vector systems, a solitary expression of the genetic transduction tag would be sufficient (Fig 1, tag  gene-expressing vector) . For transduction efficiency monitoring, monitoring of therapeutic gene expression levels as well as the duration of therapeutic gene expression and coexpression of the transduction tag together with the therapeutic gene driven from the same promoter element would be required (Fig 1, therapeutic  gene/tag gene-expressing vectors) . This could be realized either by insertion of an internal ribosomal entry site 34 in between the two coding sequences or by construction of fusion genes using appropriate linker sequences (Fig 1) . In this way, combined transcription of the transduction tag and the therapeutic gene would be ensured. Transduction tag expression simultaneously would reflect transcription and expression of the therapeutic gene on a proportional level.
An ideal transduction tag system applicable for noninvasive clinical gene therapy monitoring should have the following characteristics: (a) the transduction tag of choice should be a cell surface-expressed receptor molecule, making it easily accessible to systemically applied positron-emitting compounds; (b) it should be of human origin to avoid potential immunogenic effects that could lead to the specific elimination of transduced cells; (c) to avoid secondary biological effects, the transduction tag should be devoid of any intrinsic function (i.e., a mutated version of the wild-type gene should be expressed); (d) under physiological conditions, expression of the wild-type gene preferably should be restricted to a single body compartment to achieve low background signals in the vector-addressed body regions lying outside of this compartment. Generally, a procedure for efficient radiolabeling of the ligand specifically binding to the transduction tag receptor molecule should be at hand.
This study employed a C-terminal-deleted version of the human LNGFR (p75mut) as a prototype transduction tag for noninvasive clinical gene therapy monitoring. This decision was favored by the findings that (a) p75mut expression was found to be stable over long periods of time in tissue culture; 11,13 (b) there is no evidence for the elicitation of an anti-p75mut immune reaction that could promote the elimination of genemodified cells; 20 (c) preclinical and toxicological animal studies have not yet shown any adverse effects of p75mut expression, 18 which in part may be referred to the fact that (d) p75mut is devoid of any intrinsic signal transduction function; and (e) procedures for the efficient radiolabeling of NGF and anti-p75 mAb are at hand (Refs. 24 and 25 and this study).
Furthermore, LNGFR p75 is known to bind its natural ligands with high affinity at a binding constant (K b ) of 10 Ϫ9 M. 35 Because p75mut exhibits a deletion restricted to the cytoplasmic domain, the binding constant of p75mut is supposed to be of the same order of magnitude. Interestingly, intravenous injection of 125 I-radiolabeled NGF (into the jugular vein of a rat) resulted in a rapid uptake in distinct areas of the brain expressing p75 LNGFRs. 36 Consequently, easily detectable specific brain signals were produced. 36 Clearance of 125 I-NGF was found to be rapid (Ͻ6 hours), which relates to the fact that NGF is a protein with a small molecular mass of 13 kDa. Employing such small ligands should have an advantage for imaging due to their rapid clearance, resulting in less blood imaging. Taken together, all of these properties identify p75mut/NGF as an ideal transduction tag system.
In our study, the non-positron-emitting nuclide I-anti-p75 mAb binding to vital p75mut target cells grown on multichamber microscopic slides was further confirmed. Destruction and/or alteration of cell surfaceexpressed receptor molecules can be avoided. Binding analysis performed with the MicroImager offers additional advantages: within a measurement window of 9 mm ϫ 13 mm, a spatial resolution down to the 15-m range is provided. Furthermore, due to a special geometry, a 30,000-fold signal amplification can be obtained. Both positron-emitting as well as non-positron-emitting isotopes can be detected. Time of measurement mostly depends upon the specific activity of the ligands used and ranged from 2 hours to 30 hours in our study. With the use of this technique, a highly accurate and reliable platform for in vitro testing and in vitro screening of transduction tag systems is provided. Accordingly, other receptor-ligand couples can be tested easily and very rapidly prior to animal experiments.
Finally, applying the MicroImager-specific binding of NGF radiolabeled with the positron-emitting isotope 124 I to p75 target cells growing in vitro could be demonstrated. Thus, the first evidence for the feasibility of our PET monitoring/transduction tag approach based on the specificity of the 124 I-NGF/LNGFR interaction was provided. Because the time span for a whole body PET scan of a patient is 1-1.5 hours, it is conceivable that our prototype 124 I-NGF/p75mut transduction tag system might provide a basis for patient-individualized, noninvasive, clinical gene therapy monitoring in the future.
